Table 2. Incidence of medically diagnosed conditions and selected unadjusted and adjusted incidence ratios among human T-lymphotropic virus (HTLV)-I– and HTLV-II– infected participants and HTLV-seronegative participants, visits 2 and 3a.
| Diagnosis | HTLV seronegative (N = 799) | HTLV-I (N = 152) | HTLV-II (N = 387) | ||||
|---|---|---|---|---|---|---|---|
| Cases (%b) | Cases (%b) | IRc | Adj. IR (95% CI)d | Cases (%b) | IRc | Adj. IR (95% CI)d | |
| Pneumonia | 25 (3) | 5 (4) | 0.89 | 0.79 (0.27 to 2.29) | 19 (5) | 1.70 | 1.82 (0.98 to 3.38) |
| Acute bronchitis | 103 (14) | 21 (15) | 1.12 | 1.10 (0.68 to 1.79) | 81 (23) | 1.83 | 1.68 (1.24 to 2.29) |
| Bladder or kidney infection | 105 (14) | 31 (23) | 1.74 | 1.82 (1.19 to 2.77) | 73 (21) | 1.68 | 1.55 (1.14 to 2.11) |
| Arthritis | 32 (5) | 16 (16) | 3.19 | 2.84 (1.51 to 5.33) | 32 (12) | 2.51 | 2.66 (1.58 to 4.45) |
| Hypertension | 40 (7) | 7 (7) | 1.06 | 0.99 (0.44 to 2.22) | 20 (7) | 1.08 | 1.09 (0.63 to 1.89) |
| Asthma | 15 (2) | 2 (2) | — | — | 20 (6) | 3.38 | 3.28 (1.57 to 6.84) |
| Cancer | 21 (3) | 3 (2) | 0.81 | 0.72 (0.21 to 2.43) | 8 (2) | 0.87 | 1.10 (0.44 to 2.32) |
aOnly the first diagnosis of each condition is considered for each participant. IR, incidence ratio derived from survival analysis; CI, confidence interval. bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis. cUnadjusted incidence ratio derived from survival analysis. dAfter a backward selection process, including all potential confounding variables, the final survival analysis model contained these variables age, gender, race/ethnicity, and (for pneumonia, bronchitis, and asthma) smoking history (see Methods for details of the statistical analysis).